Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

Tré-Hardy, Marie; Cupaiolo, Roberto; Papleux, Emmanuelle; Wilmet, Alain; Horeanga, Alexandra; Antoine-Moussiaux, Thomas; Vecchia, Andrea Della; Beukinga, Ingrid; Vekemans, Marc; Blairon, Laurent

doi:10.1016/j.jinf.2021.03.025

Cited by 61 publications

(38 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified several limitations of our study: Even though titers of antibodies against S1 spike protein seem to correlate with viral neutralization studies 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , other studies including measurement of viral neutralization are expected to confirm our observations.…”

Section: Discussionmentioning

confidence: 68%

“…Very little data has been published on the evolution kinetics of antibodies after vaccination with mRNA vaccines as a whole (BNT162b2 and mRNA-1273) 9 , 10 , 11 , 12 , 13 , 14 , 15 , 18 , 19 , 20 , studies on mRNA-1273 being even rarer. The results of our study extend the evidence provided by Doria-Rose et al 11 that anti-SARS-Cov-2 antibodies persist 6 months after vaccination with mRNA-1273.…”

Section: Discussionmentioning

confidence: 99%

“…However, despite this reassuring announcement, the data currently available on the durability of the antibody response after mRNA-1273 vaccination is very limited 9 , 10 , 11 , 12 , 13 , 14 , 15 and only the study conducted by the firm Moderna goes up to 6 months after vaccination. However, other limitations appear: this study was carried out on a limited number of participants (33) only stratified according to age, without categorizing them according to their initial vaccination status and without analyzing whether other confounding factors could influence the humoral response 11 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Tré-Hardy

Cupaiolo

Wilmet

et al. 2021

Journal of Infection

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Tré-Hardy

Cupaiolo

Wilmet

et al. 2021

Journal of Infection

Self Cite

View full text Add to dashboard Cite

“…below 3 months. [2][3][4][5][6] Therefore, a longer follow-up period is needed to assess the antibody kinetics in individuals after a two-dose regimen of BNT162b2. These data are important, especially since the question about a third dose has been raised by the pharmaceutical industries which will led to important societal, logistical and economical consequences.…”

Section: Introductionmentioning

confidence: 99%

Antibody titres decline 3-month post-vaccination with BNT162b2

Favresse

Bayart

Mullier

et al. 2021

Emerging Microbes & Infections

148

116

View full text Add to dashboard Cite

Introduction: Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months postvaccination are currently lacking and are important to drive the future vaccination strategy. Methods:The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%)were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points.Results: Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37-107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46-303 days). The antibody response was higher in seropositive compared to seronegative participants. Conclusion:In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.

show abstract

“…Tré-Hardy et al in this journal recently discussed the immunogenicity of mRNA-1273 in healthcare workers [1]. Vaccines based on different strategies are being deployed across the globe to curb the recurring waves of COVID-19.…”

mentioning

confidence: 99%

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

Jolly

John

et al. 2021

Journal of Infection

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

Cited by 61 publications

References 10 publications

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Antibody titres decline 3-month post-vaccination with BNT162b2

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

Contact Info

Product

Resources

About